MobiHealth News December 7, 2021
The Series A will support Proov’s new Complete testing product.
Fertility testing company Proov announced Tuesday that it has raised $9.7 million in Series A funding.
The round was led by Hambrecht Ducera Growth Ventures with participation from SteelSky Ventures, WCC Partners, LightShip Capital, GingerBread Capital and Portfolia.
WHAT THEY DO
In early 2020, Proov scored FDA clearance for its at-home urine test measuring pregnanediol glucuronide, which can help confirm ovulation.
It’s also received a patent for using a luteinizing hormone test to determine a user’s fertility window and then a PdG test to figure out when that window has closed.
Proov offers other hormone and fertility tests, as well as an app that can let customers know...
Today's Sponsors
Today's Sponsor